Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Resolving conflict of interest The Joint Task Force on Practice Parameters (JTFPP) is
committed to ensuring that all guidelines are based on the best scientific evidence at the …

Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether
immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Myocarditis | New England Journal of Medicine Skip to main content The New England Journal
of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology Clinical Medicine …

Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …